

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-7. (Cancel)

8. (Currently Amended) An isolated antibody to an isolated peptide of the general formula:

G-X₁-X₂-R (SEQ ID NO: 1)

and wherein G is glutamate or glutamine;

X₁ is a bond or an amino acid selected from the group consisting of isoleucine, valine, methionine, alanine, and phenylalanine;

X₂ is an amino acid selected from the group consisting of aspartate, glutamate, and asparagine; and

R is a tripeptide wherein each of the amino acids of said tripeptide are selected from the group consisting of proline, isoleucine, aspartate, alanine, glycine, serine, valine, lysine, glutamate, glutamine, threonine, leucine, methionine, phenylalanine, arginine, and asparagine;

and wherein the antibody binds to a 6C5 antigen.

9. (Previously Presented) The antibody according to claim 8, wherein said antibody is a monoclonal antibody.

10. (Previously Presented) The antibody according to claim 8, wherein said antibody is 6C5.

11. (Previously Presented) The antibody according to claim 8, wherein said antibody is produced by the cell line F6-6C5-H4 (ATCC No. PTA-1358).

12. (Previously Presented) The antibody according to claim 8, wherein said antibody is a polyclonal antibody.

13. (Previously Presented) The cell line F6-6C5-H4 (ATCC No. PTA-1358).

14. (Previously Presented) A method of treating a yeast infection in a patient in need of such treatment comprising administering to said patient a composition comprising an active agent, wherein said active agent is an antibody according to claim 8.

15. (Previously Presented) A method of detecting a hydrophobic binding domain in a sample containing multiple components, comprising the steps of:
providing an antibody according to claim 8, wherein said antibody is labeled with a detectable marker;
contacting the sample with an antibody according to claim 8; and
isolating any resulting complexes formed between the sample components and the labeled antibodies.

16. (Previously Presented) The method of claim 15, wherein said detection is performed *in vivo*.

17. (Previously Presented) The method of claim 15, wherein said detection is performed *in vitro*.

18. (Previously Presented) A method of isolating a hydrophobic binding domain comprising the steps of:
providing an antibody according to claim 8, wherein said antibody is labeled with a detectable marker, and wherein said antibody is bound to a solid support;
contacting a sample containing multiple components with said antibody; and
washing the solid support to remove unbound material.

Claims 19-48. (Cancel).

49. (Previously Presented) The antibody of claim 8, wherein said peptide comprises Glutamate-Isoleucine-Aspartate-Proline-Isoleucine-Aspartate.

50. (Currently Amended) The antibody of claim 9 8, wherein the peptide consists of Glutamate-Isoleucine-Aspartate-Proline-Isoleucine-Aspartate.

51. (Previously Presented) The antibody of claim 49, wherein the antibody is a monoclonal antibody.

52. (Previously Presented) The antibody of claim 50, wherein the antibody is a monoclonal antibody.

53. (Previously Presented) The antibody of claim 49, wherein the antibody is a polyclonal antibody.

54. (Previously Presented) The antibody of claim 50, wherein the antibody is a polyclonal antibody.